Anti-Fibrinolytic Drugs - Southern Africa

Southern Africa

In Southern Africa, the Anti-Fibrinolytic Drugs market is expected to witness significant growth in the coming years.
By 2024, the revenue is projected to reach US$56.45m.
Furthermore, it is anticipated that the market will experience a steady annual growth rate (CAGR 2024-2029) of 4.24%, leading to a market volume of US$69.49m by 2029.
When compared globally, United States is expected to generate the highest revenue in this market.
In 2024, the revenue United States is estimated to reach a staggering US$9,858.00m.
This indicates the dominance of the United States in the Anti-Fibrinolytic Drugs market.
Southern Africa is experiencing a growing demand for anti-fibrinolytic drugs as the region grapples with an increasing prevalence of cardiovascular diseases.

Key regions: United Kingdom, Brazil, Europe, France, Canada

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Fibrinolytic Drugs market in Southern Africa is experiencing notable growth in recent years.

Customer preferences: Anti-Fibrinolytic Drugs are primarily used to prevent excessive bleeding during surgeries and medical procedures. The increasing prevalence of chronic diseases and the rising number of surgeries are driving the demand for these drugs. Patients prefer these drugs as they are effective in controlling bleeding and have minimal side effects.

Trends in the market: South Africa dominates the Anti-Fibrinolytic Drugs market in Southern Africa due to the presence of well-established healthcare infrastructure and a high number of surgeries. The market is expected to grow further due to the increasing number of surgeries in the region. Additionally, the growing geriatric population is also contributing to the growth of the market as they are more prone to chronic diseases and require more surgeries.

Local special circumstances: The South African government has implemented various initiatives to improve healthcare infrastructure and services, which is expected to boost the demand for Anti-Fibrinolytic Drugs. However, the lack of awareness regarding the use of these drugs among the general population and healthcare professionals is a major challenge in the market.

Underlying macroeconomic factors: The growth of the Anti-Fibrinolytic Drugs market in Southern Africa is primarily driven by the increasing prevalence of chronic diseases and the rising number of surgeries. The growing geriatric population and the improving healthcare infrastructure are expected to further fuel the growth of the market. However, the lack of awareness regarding the use of these drugs is a major challenge that needs to be addressed.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.